GIP vs Tirzepatide
Written by Aaron CuhaReviewed Sep 2026
The short answer
The natural hormone, against the drug that added its switch to a GLP-1 base. What the GIP switch does on its own is still argued about, including whether switching it on or blocking it is the useful way to go. That is why MariTide blocks the same switch tirzepatide turns on.
- GIP people
- 10
- GIP nulls
- 0
- Tirzepatide people
- 22,802
- Tirzepatide nulls
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 10 people given it
Dose
Approved titration: 2.5, 5, 7.5, 10, 12.5 and 15 mg
2.5, 5, 7.5, 10, 12.5 and 15 mg
The approved tirzepatide ladder, in mg.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
GIPGlucose-dependent insulinotropic polypeptide
GIP is one of two gut hormones that tell your pancreas to release insulin after a meal. It is the G in tirzepatide and the other drugs that hit two or three hormone targets. In people, drugs that switch its receptor on and drugs that block it have both caused weight loss. Nobody has explained why.
Column B
TirzepatideTirzepatide (dual GIP/GLP-1 receptor agonist)
A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone.
Side by side, on the facts we can check
| What we compare | GIP | Tirzepatide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Not an approved drug, and not used as a treatment. Drugs that work on its receptor are approved, including tirzepatide. | FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea) |
| Half-life | Short. Inactivated by dipeptidyl peptidase-4. No single agreed numeric half-life for intact human GIP resolved in our sources, so none is asserted here. | ~5 days |
| Molecular weight | Mature peptide is 42 amino acids (residues 52 to 93 of the 153-residue precursor, UniProt P09681). The precursor is 17,108 Da; we do not assert a mature-peptide mass because no source we loaded states one. | 4,813.5 Da |
| How it works | GIP docks on its own receptor. In the insulin-making cells of the pancreas, that boosts insulin release when blood sugar is high. When blood sugar is normal, it does not push insulin out. The same receptor also sits in fat, bone and the brain, and most of the recent human work is about those places. An enzyme called DPP-4 breaks GIP down fast. That is the same enzyme the DPP-4 diabetes pills block. | It switches on two receptors at once, GIP and GLP-1. Both answer gut hormones after a meal. Together they make the body release insulin when blood sugar is high, hold back glucagon, slow how fast the stomach empties and turn down hunger. The GIP part is thought to add its own effect on how the body handles sugar and fat. |
| Studies in people | 6 | 11 |
| Evidence | Limited: 2 completed trials, 10 people given it | Strong: 9 completed trials, 22,802 people given it |
| Legal status, US | Not a drug; a natural body hormone, given only by drip in research | FDA-approved, prescription only |
Frequently asked questions
What is the difference between GIP and Tirzepatide?
GIP: GIP is one of two gut hormones that tell your pancreas to release insulin after a meal. It is the G in tirzepatide and the other drugs that hit two or three hormone targets. In people, drugs that switch its receptor on and drugs that block it have both caused weight loss. Nobody has explained why. Tirzepatide: A once a week shot that works on two hunger and blood sugar signals, GIP and GLP-1. In studies it led to more weight loss and lower blood sugar than drugs that work on GLP-1 alone.
Which has stronger research evidence, GIP or Tirzepatide?
Each compound gets a band worked out from facts we counted, with the math shown. GIP is Limited (2 completed trials, 10 people given it). Tirzepatide is Strong (9 completed trials, 22,802 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are GIP and Tirzepatide FDA-approved?
GIP: Not an approved drug, and not used as a treatment. Drugs that work on its receptor are approved, including tirzepatide.. Tirzepatide: FDA-approved (Mounjaro for type 2 diabetes and, from August 2026, to lower the risk of major heart and blood vessel problems in people with type 2 diabetes; Zepbound for weight management and sleep apnea).
Related posts
Blog articles that cover GIP or Tirzepatide, newest first.
- Dispatch / Sep 27, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 27, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 27, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 27, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.